Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Orthopedic Surgery · Diffuse-type Tenosynovial Giant Cell Tumor

Open vs Arthroscopic Diffuse TGCT Surgery: Which Is Right?

At a Glance

For diffuse TGCT of the knee, neither surgical approach is always best. Arthroscopy may mean less pain and faster early recovery, while open or combined surgery can better reach disease in the back of the knee. MRI findings and surgeon expertise guide the choice, followed by monitoring for recurrence.

Diffuse-type tenosynovial giant cell tumor (TGCT), formerly called diffuse pigmented villonodular synovitis (PVNS), is a rare, usually noncancerous (benign) condition. It can be locally aggressive, meaning it spreads extensively throughout the joint lining (synovium) and can cause significant damage to the joint, but it rarely spreads to other organs. The primary goal of surgery is a synovectomy—removing as much of the diseased joint lining as safely possible.

Choosing between open and arthroscopic surgery is a complex decision, and there is no universally “best” approach. The choice depends on the specific location of your tumor, the expertise of your surgeon, and the trade-off between complete removal and the risk of surgical complications.

Understanding the Surgical Approaches

Arthroscopic Surgery

Arthroscopy is a minimally invasive approach. The surgeon makes several small incisions (multiportal) and uses a tiny camera and specialized instruments to visualize and remove the tumor.

  • The Pros: This approach generally causes less tissue disruption. For many patients, it leads to a faster early recovery, less initial pain, and a shorter hospital stay [1].
  • The Cons: Diffuse TGCT can involve multiple deep recesses in the knee, especially in the back (posterior compartment) [2]. It can be technically challenging to safely reach and remove all the tumor tissue using only an arthroscope, particularly if the tumor wraps around important structures [3][4]. Leaving tumor tissue behind can increase the chance of it growing back (recurrence) [3].

Open Surgery

Open surgery involves one or more larger incisions, giving the surgeon direct access to the joint and surrounding tissues.

  • The Pros: It provides broader exposure. Surgeons can more easily access large tumor masses, disease that has grown outside the joint capsule (extra-articular), and areas near critical blood vessels and nerves [5][6].
  • The Cons: Because it requires more extensive cutting of skin, muscle, and joint tissue, the early recovery is often more difficult and painful [1][7]. Functional recovery can be a longer process, sometimes taking 6 to 12 months for maximum improvement [7].

The Combined Approach

For extensive disease, specialized surgeons may recommend a combined approach. This often involves using arthroscopy to clear the front of the knee, followed by an open incision in the back to safely access deep tumor tissue [6][8].

Comparing the Approaches

Feature Arthroscopic Surgery Open or Combined Surgery
Best Used For Disease mostly confined to the front of the knee or easily accessible areas [6]. Large tumors, disease in the back of the knee, or extending outside the joint [5][6].
Tissue Disruption Lower, minimal incisions [1]. Higher, larger incisions and more tissue cutting [5].
Early Recovery Typically faster, with potential for earlier mobility [1]. Usually slower, may require longer hospital stay and delayed weight-bearing [7].

Recurrence: What the Evidence Says

Because diffuse TGCT spreads widely, regrowth (recurrence) is a major challenge with any surgical approach. Some research suggests that arthroscopic surgery alone may have a higher recurrence rate than open surgery [9][10]. For example, one large analysis estimated the annual recurrence incidence at 0.11 per patient-year after arthroscopy compared to 0.07 after open surgery, calculating a 1.56-fold higher risk for arthroscopy [9].

However, these numbers must be interpreted carefully. In practice, surgeons typically select open surgery for patients with larger, more complicated tumors, and arthroscopy for less extensive disease [9][5]. Furthermore, some studies show no significant difference in recurrence between the approaches [11]. Ultimately, recurrence can happen years after any type of surgery, making long-term monitoring essential [12].

How the Decision is Made

The surgical plan should be individualized based on a detailed MRI map of your knee [2].

  • MRI Findings: If the MRI shows the tumor involves the back of the knee, extends outside the joint, or surrounds major nerves and blood vessels, this may favor an open or combined approach to safely reach it [5][6][4].
  • Risks and Complications: Both surgeries carry general risks like infection, bleeding, and blood clots [9][6]. Open surgery in the back of the knee carries specific risks of injury to the popliteal vessels and major nerves [5][1].
  • Alternatives: Surgery is not the only option. If complete removal would cause severe joint damage or nerve injury, or if you have recurrent disease, your team may discuss observation, staging the surgery, or systemic medical treatments (such as CSF1-pathway inhibitors like pexidartinib) in a multidisciplinary setting.

Recovery Expectations

Both open and arthroscopic surgeries can significantly improve pain, swelling, and knee function [7][6].

However, joint stiffness is a very common challenge after any extensive synovectomy [6][7]. Rehabilitation is critical. While early milestones like walking and returning to work vary by procedure, full recovery of range of motion can take months. If the knee becomes too stiff, some patients may require prolonged physical therapy or a manipulation under anesthesia (a procedure where the doctor gently bends the knee while you are asleep to break up scar tissue) [6].

Because TGCT can return, you will likely need a personalized long-term surveillance plan, which may include regular clinical exams and follow-up MRIs to monitor for new growth [12].

Common questions in this guide

How do open and arthroscopic surgeries differ for diffuse TGCT?
Both operations aim to remove diseased joint lining, called a synovectomy. Arthroscopy uses small incisions and a camera, while open surgery uses a larger incision for broader access to the joint and nearby tissues. Arthroscopy often offers an easier early recovery, but open surgery may reach large tumors or disease in the back of the knee or outside the joint more effectively.
Is arthroscopic surgery better than open surgery for diffuse TGCT?
There is no single best approach for everyone. Arthroscopy may cause less early pain and tissue disruption, but open or combined surgery can be better for extensive disease that is hard to reach. MRI findings, tumor location, and the surgeon’s experience help determine which option offers the safest and most complete removal.
Does arthroscopic surgery make diffuse TGCT more likely to come back?
Research is mixed. Some analyses have found higher recurrence after arthroscopy, but open surgery is often chosen for larger and more complicated tumors, which makes direct comparisons difficult. Diffuse TGCT can recur after either approach, so long-term examinations and follow-up MRI scans are important.
How long does recovery take after diffuse TGCT surgery?
Arthroscopic surgery often allows faster early mobility, while open or combined surgery can require a longer hospital stay and a slower return to normal activity. Recovery of knee movement can take months, and maximum improvement after extensive open surgery may take 6 to 12 months. Physical therapy is important, and stiffness can persist despite treatment.
How does my MRI affect the choice between open and arthroscopic TGCT surgery?
An MRI shows where the tumor is located and whether it extends into the back of the knee, outside the joint, or around major nerves and blood vessels. Those findings may favor open or combined surgery, while disease limited to accessible areas may be suitable for arthroscopy. The surgical plan should balance complete removal with the risk of damaging important structures.
What if the surgeon cannot safely remove all of the diffuse TGCT?
The treatment team may consider observation, surgery in stages, or a systemic medicine such as the CSF1-pathway inhibitor pexidartinib. These options are discussed when removing all visible disease could cause serious joint, nerve, or blood-vessel damage, or when the tumor has returned. A multidisciplinary team can help weigh tumor control, side effects, and function.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Tenosynovial giant cell tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What does my MRI show about the tumor's location, particularly in the back of my knee or outside the joint space?
  2. 2.Based on my specific MRI pattern, what are the pros and cons of your recommended surgical approach?
  3. 3.What is your personal experience and volume treating diffuse TGCT of the knee, and has my case been reviewed by a multidisciplinary tumor board?
  4. 4.What are the major risks of this surgery, and how will we protect my nerves and blood vessels?
  5. 5.What is the expected early recovery timeline (weight-bearing, crutches, hospital stay), and what is the long-term physical therapy plan?
  6. 6.If we cannot safely remove all the visible tumor, what are our alternative options, such as systemic treatments or observation?

References

References (12)
  1. 1

    Open versus arthroscopic surgery for diffuse tenosynovial giant-cell tumours of the knee: a systematic review.

    Quaresma MB, Portela J, Soares do Brito J

    EFORT open reviews 2020; (5(6)):339-346 doi:10.1302/2058-5241.5.200005.

    PMID: 32655889
  2. 2

    Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints.

    Kim DE, Kim JM, Lee BS, et al.

    Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA 2018; (26(11)):3508-3514 doi:10.1007/s00167-018-4942-2.

    PMID: 29637236
  3. 3

    Arthroscopic Synovectomy for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis in the Posterior Knee Using the Posterior Trans-Septal Portal Technique.

    Moran J, Miller MD, Schneble CA, et al.

    JBJS essential surgical techniques 2022; (12(1)) doi:10.2106/JBJS.ST.21.00051.

    PMID: 35685235
  4. 4

    Diffuse pigmented villonodular synovitis in knee joint: diagnosis and treatment.

    Temponi EF, Barros AAG, Paganini VO, et al.

    Revista brasileira de ortopedia 2017; (52(4)):450-457 doi:10.1016/j.rboe.2017.06.008.

    PMID: 28884104
  5. 5

    Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).

    Lingamfelter M, Novaczyk ZB, Cheng EY

    JBJS essential surgical techniques 2022; (12(2)) doi:10.2106/JBJS.ST.21.00035.

    PMID: 36741035
  6. 6

    What Are the Recurrence Rates, Complications, and Functional Outcomes After Multiportal Arthroscopic Synovectomy for Patients With Knee Diffuse-type Tenosynovial Giant-cell Tumors?

    Yao L, Li Y, Li T, et al.

    Clinical orthopaedics and related research 2024; (482(7)):1218-1229 doi:10.1097/CORR.0000000000002934.

    PMID: 38153106
  7. 7

    Diffuse-Type Tenosynovial Giant Cell Tumor of the Knee: Clinical Course After Anterior Open Synovectomy.

    Bruschi A, Staals E, Sambri A, et al.

    Current oncology (Toronto, Ont.) 2025; (32(6)) doi:10.3390/curroncol32060342.

    PMID: 40558285
  8. 8

    Functional Outcomes and Recurrence After Arthroscopy-Based Treatment of Pigmented Villonodular Synovitis of the Knee: A 20-Year Single-Center Series.

    Konstantinou E, Koskiniotis A, Koutalos A, et al.

    Cancers 2026; (18(7)) doi:10.3390/cancers18071178.

    PMID: 41976400
  9. 9

    Arthroscopic Versus Open Management of Diffuse-Type Tenosynovial Giant Cell Tumor of the Knee: A Meta-analysis of Retrospective Cohort Studies.

    Chandra AA, Agarwal S, Donahue A, et al.

    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews 2021; (4(12)) doi:10.5435/JAAOSGlobal-D-21-00217.

    PMID: 34882586
  10. 10

    The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis.

    Mollon B, Lee A, Busse JW, et al.

    The bone & joint journal 2015; (97-B(4)):550-7 doi:10.1302/0301-620X.97B4.34907.

    PMID: 25820897
  11. 11

    Clinical outcomes of diffuse PVNS of the knee following arthroscopic complete synovectomy±posterior open resection.

    Kerschner A, King D, Vetter C

    Journal of orthopaedics 2021; (28()):34-40 doi:10.1016/j.jor.2021.10.001.

    PMID: 34759596
  12. 12

    Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.

    Mastboom MJL, Palmerini E, Verspoor FGM, et al.

    The Lancet. Oncology 2019; (20(6)):877-886 doi:10.1016/S1470-2045(19)30100-7.

    PMID: 31029509

This page is for informational purposes only and does not constitute medical advice. Discuss your MRI, surgical risks, and treatment plan for diffuse TGCT with your orthopedic tumor specialist.